[Advanced Disease Situations with Organic Brain Changes].

Advanced Disease Situations with Organic Brain Changes The majority of patients in specialized long-term palliative care facilities have organic brain changes. These disorders are characterized by complex neurological and psychological symptoms. Many of these patients take a lot of time, need a lot of care and treatment and also require appropriate environmental conditions.

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose-escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors.

Patients And Methods: Patients aged 18 years or older with advanced solid tumors refractory to standard treatment were recruited.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Purpose: BI 2536 is a novel, potent, and highly specific inhibitor of polo-like kinase 1 (Plk1), which has an essential role in the regulation of mitotic progression. The aim of this trial was to identify the maximum tolerated dose (MTD) of BI 2536 and to determine the safety, pharmacokinetics, and antitumor activity in patients who had advanced solid tumors.

Patients And Methods: This phase I trial followed an open label, toxicity-guided, dose-titration design.